- Report
- March 2025
- 93 Pages
Global
From €5316EUR$5,600USD£4,484GBP
- Report
- March 2025
- 175 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- May 2024
- 137 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Report
- May 2024
- 131 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Report
- August 2021
- 177 Pages
Global
From €4225EUR$4,450USD£3,563GBP
- Report
- January 2024
- 107 Pages
Global
From €3500EUR$3,949USD£3,056GBP
- Report
- July 2023
- 105 Pages
Global
From €3500EUR$3,949USD£3,056GBP
- Report
- March 2025
- 50 Pages
Global
From €2516EUR$2,650USD£2,122GBP
- Report
- March 2025
- 50 Pages
Global
From €2516EUR$2,650USD£2,122GBP
- Book
- January 2010
- 616 Pages
Diltiazem is a calcium channel blocker used to treat hypertension, angina, and certain types of arrhythmias. It is a commonly prescribed cardiovascular drug, and is available in both immediate-release and extended-release formulations. Diltiazem is also used to treat chronic stable angina, and is sometimes used in combination with other drugs to treat acute coronary syndrome. It is also used to treat atrial fibrillation and atrial flutter.
Diltiazem is available in a variety of forms, including tablets, capsules, and injectable solutions. It is also available as a topical cream for the treatment of anal fissures. The drug is generally well tolerated, with few side effects.
The diltiazem market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include Pfizer, Novartis, Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more